Wordt geladen...
Futility Rules in Bioequivalence Trials with Sequential Designs
Health Canada, the US Food and Drug Administration, as well as the European Medicines Agency consider sequential designs acceptable for bioequivalence studies as long as the type I error is controlled at 5%. The EU guideline explicitly asks for specification of stopping rules, so the goal of this wo...
Bewaard in:
| Hoofdauteur: | |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Springer US
2013
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3889523/ https://ncbi.nlm.nih.gov/pubmed/24218038 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1208/s12248-013-9540-0 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|